Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study

Psychiatry Res. 2013 Jan 30;211(1):88-91. doi: 10.1016/j.pscychresns.2012.09.004. Epub 2012 Nov 10.

Abstract

We hypothesized that atomoxetine (ATMX) would produce similar brain effects in attention-deficit/hyperactivity disorder (ADHD) as those of methylphenidate (MPH). Eleven ADHD adults performed the Multi-Source Interference Task (MSIT) during functional magnetic resonance imaging (fMRI) at baseline and after 6 weeks of ATMX treatment. ATMX was associated with increased fMRI activation of dorsolateral prefrontal cortex, parietal cortex and cerebellum but not dorsal anterior midcingulate cortex (daMCC). These results suggest that ATMX and MPH have similar but not identical brain effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology*
  • Adrenergic Uptake Inhibitors / therapeutic use
  • Adult
  • Atomoxetine Hydrochloride
  • Attention Deficit Disorder with Hyperactivity / drug therapy
  • Attention Deficit Disorder with Hyperactivity / physiopathology*
  • Frontal Lobe / drug effects*
  • Frontal Lobe / physiopathology
  • Humans
  • Magnetic Resonance Imaging
  • Nerve Net / drug effects*
  • Nerve Net / physiopathology
  • Parietal Lobe / drug effects*
  • Parietal Lobe / physiopathology
  • Pilot Projects
  • Propylamines / pharmacology*
  • Propylamines / therapeutic use

Substances

  • Adrenergic Uptake Inhibitors
  • Propylamines
  • Atomoxetine Hydrochloride